He survived meningococcal disease.
Not everyone does.

To help prevent meningococcal disease, vaccinate your adolescent patients with 2 different types of vaccines, covering the 5 vaccine-preventable meningococcal serogroups—one for serogroups A, C, W-135, and Y and one for serogroup B.1

The person depicted is a model used for illustrative purposes only.

Are you sure you’re following the CDC recommendation on MenB vaccination?

If you don’t include patients and parents in the decision to vaccinate, then you’re not. Make sure you know how to incorporate the meningococcal serogroup B disease (MenB) discussion in your protocol.


CDC=Centers for Disease Control and Prevention.

Vaccination may not protect all recipients.

The people in these videos are advocates for meningococcal disease vaccination. Some were compensated by GSK for their participation. These videos are personal experiences; other people's experiences with meningococcal disease may be different.

References: 1. Centers for Disease Control and Prevention. Meningococcal vaccination for adolescents: Information for healthcare professionals. http://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Reviewed July 26, 2019. Accessed March 18, 2020. 2. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015;261-278. http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed July 12, 2018. 3. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 4. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15. 5. Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479. 6. Vyse A, Anonychuk A, Jäkel A, et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604. 7. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR-2):1-28. 8. MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 6th ed. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html. Updated April 1, 2014. Accessed July 12, 2018. 9. Meningococcal disease: causes and transmission. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/about/causes-transmission.html. Updated June 11, 2015. Accessed July 12, 2018. 10. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs). Neisseria meningitidis, 2005-2014. Centers for Disease Control and Prevention website. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed July 12, 2018.

BEXWCNT200001 March 2020